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Abstract
© 2018  Kovac,  Litvin,  Aliev,  Zakirova,  Rutland,  Kiyasov  and  Rizvanov.  This  clinical  study
describes the intralesional application of the plasmid DNA encoding two therapeutic species-
specific growth factors: vascular endothelial  growth factor (VEGF164) and fibroblast growth
factor 2 (FGF2) in seven horses to restore naturally occurring injuries of the superficial digital
flexor tendon (SDFT) (tendinitis) and in three horses with suspensory ligament branch desmitis.
Following application all  horses were able to commence a more rapid exercise program in
comparison to standardized exercise programs. Clinical observation and ultrasonic imaging was
used to evaluate the regeneration rate of the tendon and ligament injury recovery and to
confirm the safety of this gene therapy in horses, throughout a 12 month period. Follow-up data
of the horses revealed a positive outcome including significant ultrasonographic and clinical
improvements in 8 out of 10 horses with SDFT and suspensory ligament branch lesions, with
return to their pre-injury level of performance by 2-6 months after the completion of treatment.
The  ninth  horse  initially  presenting  with  severe  suspensory  ligament  branch  desmopathy,
showed no significant ultrasonographic improvements in the first 2 months after treatment,
however, it improved clinically and became less lame. The final horse, presenting with severe
tendinitis of the SDFT returned to their pre-injury level of performance, but experienced re-injury
6  months  after  treatment.  This  data  is  highly  promising,  however,  further  research  in
experimental models, with the histopathological, immunohistochemical and gene expression
evaluation of the equine tendon/ligament after gene therapy application is required in order to
fully understand the mechanisms of action. This treatment and the significant clinical impacts
observed represents an important advancement in the field of medicine.
http://dx.doi.org/10.3389/fphar.2018.00978
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